Hepatitis B reactivation and timing for prophylaxis

dc.contributor.authors	Tuna, N; Karabay, O;
dc.date.accessioned	2020-02-27T08:44:17Z
dc.date.available	2020-02-27T08:44:17Z
dc.date.issued	2015
dc.identifier.citation	Tuna, N; Karabay, O; (2015). Hepatitis B reactivation and timing for prophylaxis. WORLD JOURNAL OF GASTROENTEROLOGY, 21, 2264-2263
dc.identifier.issn	1007-9327
dc.identifier.uri	https://doi.org/10.3748/wjg.v21.i7.2263
dc.identifier.uri	https://hdl.handle.net/20.500.12619/66817
dc.description.abstract	It is known that immunotherapy and cancer chemotherapy may cause hepatitis B virus (HBV) reactivation in hepatitis B surface antigen carriers and inactive chronic hepatitis B patients. Guidelines recommend antiviral prophylaxis regardless of HBV DNA levels to prevent reactivation. We read from the article written by Liu et al that Lamivudine was given inadequate time for antiviral prophylaxis.
dc.language	English
dc.publisher	BAISHIDENG PUBLISHING GROUP INC
dc.subject	Gastroenterology & Hepatology
dc.title	Hepatitis B reactivation and timing for prophylaxis
dc.type	Letter
dc.identifier.volume	21
dc.identifier.startpage	2263
dc.identifier.endpage	2264
dc.contributor.department	Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor	Karabay, Oğuz
dc.relation.journal	WORLD JOURNAL OF GASTROENTEROLOGY
dc.identifier.wos	WOS:000349667100037
dc.identifier.doi	10.3748/wjg.v21.i7.2263
dc.identifier.eissn	2219-2840
dc.contributor.author	Nazan Tuna
dc.contributor.author	Karabay, Oğuz